Cerenome, Inc.
CNSY Nasdaq· Surgical & Medical Instruments & Apparatus
Last close · Oct 23, 2026
$1.64
KIRA · Stoqly’s AI analyst, in plain words
- Cerenome, Inc. had $5.2M of revenue in fiscal 2025, down 10.5% on the year before.
- Its operating margin was −293.5%, down 41.1 pts: of every 100 in sales, about −293 is left after running the business.
- Cerenome, Inc. lost $22.4M in fiscal 2025.
- Free cash flow was −$20.8M in fiscal 2025, −399.8% of revenue.
Market cap
$11.3M
P/E
0.1x
Revenue
$5.2M
Net income
−$22.4M
Free cash flow
−$20.8M
Operating margin
−293.5%
Cerenome, Inc. in 30 seconds · fiscal 2025
Are sales growing?
−10.5%
No. Sales fell 10.5% last year.
Does it make a profit?
−429.4%
No. It lost money last year.
Does profit turn into cash?
−399.8%
No. It spent more cash than it brought in.
How healthy are the accounts?
3 / 7
Weak. It passes 3 of 7 health tests.
How is the share priced?
0.1x
One share costs 0.1 times its yearly profit per share.
What Cerenome, Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 12, 2026
- Legal name
- CERENOME, INC.
- CIK
- 0001095981
Cerenome, Inc. · CNSY
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | — | — | $4.9M | $5.8M | $5.2M |
| Revenue growth | — | — | — | 18.5% | −10.5% |
| Operating margin | — | — | −271.1% | −252.3% | −293.5% |
| Net income | −$13.4M | −$20.3M | −$13.3M | −$13.0M | −$22.4M |
| Net margin | — | — | −271.0% | −222.8% | −429.4% |
| Diluted EPS | −$1.11 | −$11.58 | −$4.24 | −$2.34 | −$0.29 |
| Cash | |||||
| Cash from operations | −$10.3M | −$13.0M | −$12.9M | −$10.6M | −$20.8M |
| Capital expenditure | — | — | $0.2M | $0.1M | $0.1M |
| Free cash flow | — | — | −$13.0M | −$10.7M | −$20.8M |
| FCF margin | — | — | −264.8% | −183.7% | −399.8% |
| Share count change | 173.0% | −85.5% | 79.4% | 145.2% | 910.3% |
| Debt and strength | |||||
| Cash and short-term investments | $18.4M | $18.1M | $8.6M | $3.6M | $8.6M |
| Debt incl. finance leases | $6.6M | $5.4M | $4.0M | — | — |
| Shareholders' equity | $10.8M | $6.4M | −$1.3M | −$8.9M | $4.0M |
| Current ratio | 3.4x | 1.8x | 0.9x | 0.3x | 1.2x |
| Interest coverage | −13.4x | −27.7x | −33.7x | −82.1x | −27.9x |
| Returns and quality | |||||
| Return on equity | −193.3% | −234.7% | −522.5% | — | — |
| Return on tangible equity | −128.0% | −333.9% | — | — | −680.2% |
| Piotroski F-score | 4 | 3 | 1 | 2 | 3 |
| Altman Z'' | −64.9 | −66.2 | −146.0 | −268.2 | −107.8 |
Insiders bought, 12 months
$0.0M
1 insider
Insiders sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Cerenome, Inc. · CNSY
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $1.64 a share, the company is worth $11.3M: 0.1 times its earnings of the last four quarters.
Source: SEC EDGAR XBRL filings (CIK 0001095981). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.